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Abstract
Epidermolysis bullosa (EB) is a group of rare heterogeneous, genetic disorders. Cur-
rently, there is no effective pharmacological or genetic therapy for all EB subtypes.
Dry extract from birch bark and betulin upregulate some pro-inflammatory mediators
and downregulate others. The increase in pro-inflammatory cytokines is temporary
and attenuated over long-term treatment. This inflammatory stimulus is thought to
be prerequisite for a secondary anti-inflammatory response. Dry extract from birch
bark and its active marker substances have also been shown to increase the migra-
tion of primary human keratinocytes, accelerate wound closure, and promote differ-
entiation of keratinocytes in vitro and in vivo—processes that are essential for
reepithelialization and maintenance of the skin barrier. Comprehensive clinical data
are available to support the use of Oleogel-S10 in the treatment of partial thickness
wounds of different etiologies, and a proof-of-concept Phase 2 study in patients with
dystrophic EB has suggested the potential for faster reepithelialization of wounds
treated with Oleogel-S10.
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1 | OLEOGEL-S10: PHYSICAL AND
CHEMICAL PROPERTIES
Oleogel-S10 is a wound-healing gel containing dry extract from
Betulae cortex (birch bark)—also referred to as triterpene extract
(Laszczyk, Jager, Simon-Haarhaus, Scheffler, & Schempp, 2006). The
gel contains 90% wt/wt sunflower oil, and 10% wt/wt dry extract
from birch bark, of which the majority is betulin (72–88% wt/wt).
Additional active marker substances include betulinic acid, lupeol,
oleanolic acid, and erythrodiol (molecular structures are shown in
Figure S1) (Bickel, 2005; European Medicines Agency, 2015). The dry
extract from birch bark has galenic properties causing oils to gel, for-
ming semisolid, viscoelastic gels with thixotropic properties. These
have greater viscosity at higher temperatures than at room tempera-
ture. This thixotropic property means formulations of dry extract from
birch bark liquefy under movement for conveniently application, and
then revert back to a gel-like state (Bickel, 2005; Grysko & Dan-
iels, 2013).
2 | STUDIES ON THE EFFECT MECHANISM
OF DRY EXTRACT FROM BIRCH BARK AND
ITS COMPONENTS
The physiological process of wound healing has been described as a
three-stage process of inflammation, tissue formation, and wound
closure/remodeling (Valero, Javierre, Garcia-Aznar, Menzel, & Gomez-
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Benito, 2015). In various studies, dry extract from birch bark and its
active marker substances have been shown to have activity in the first
two stages of the wound healing process (Alakurtti, Makela,
Koskimies, & Yli-Kauhaluoma, 2006; Bernard, Scior, Didier, Hibert, &
Berthon, 2001; Ci et al., 2017; Doller et al., 2008; Ebeling et al., 2014;
Galgon, Wohlrab, & Drager, 2005; Laszczyk, 2009; Lee, Nam, Kim, &
Lee, 2006; Recio, Giner, Manez, & Rios, 1995; Saleem, Afaq, Adhami, &
Mukhtar, 2004; Suksamrarn et al., 2006; Takada & Aggarwal, 2003;
Tseng & Liu, 2004; Wardecki et al., 2016; Woelfle et al., 2010; Yadav,
Prasad, Sung, Kannappan, & Aggarwal, 2010; Yogeeswari & Sriram,
2005; Yun et al., 2003). An overview of this activity is presented in
Figure 1. In the sections that follow, the effects of dry extract from
birch bark are described according to these two stages.
2.1 | Effects on inflammation
Data on the early inflammatory stages of wound healing show that
dry extract from birch bark and betulin have a modulatory role where
by some pro-inflammatory mediators are upregulated and others are
downregulated (Ebeling et al., 2014).
Specifically, dry extract from birch bark and betulin both
upregulate pro-inflammatory cytokines cyclooxygenase 2 (COX-2),
interleukin (IL)-6, and IL-8 in primary human keratinocytes cells. This
upregulation occurs at the level of both RNA (within 8–24 hr) and
protein (by 24 hr) (Ebeling et al., 2014). The increase in mRNA halflife
of immunocompetent peptides is due to an mRNA-stabilizing effect of
dry extract from birch bark and betulin. This process involves p38
mitogen-activated protein kinase and human antigen R (Doller et al.,
2008; Ebeling et al., 2014). Additionally, increased expression of IL-6
and COX-2 has been confirmed in a porcine wound healing model and
in human skin punch biopsies challenged with dry extract from birch
bark and betulin (Ebeling et al., 2014). The increase in pro-
inflammatory cytokine expression seen in studies of dry extract of
birch bark and its active marker substances are temporary and are
attenuated during the course of long-term treatment (Ebeling
et al., 2014).
Anti-inflammatory activity of betulin, oleanolic acid, erythrodiol,
betulinic acid, and lupeol has been shown in various experimental
models (Bernard et al., 2001; Ci et al., 2017; Laszczyk, 2009; Saleem
et al., 2004; Takada & Aggarwal, 2003; Tseng & Liu, 2004; Yadav
et al., 2010; Yogeeswari & Sriram, 2005). Exact mechanisms of these
activities are not yet completely understood, however, and further
investigations are required to fully elucidate and delineate pro-
inflammatory and anti-inflammatory effects of Oleogel-S10 and its
various active marker substances.
2.2 | Effects on new tissue formation
Dry extract from birch bark and its components betulin, lupeol, and
erythrodiol influence the new tissue formation stage (Stage 2) of
wound healing by promoting keratinocyte migration, possibly by
increasing the formation of actin filopodia, lamellipodia, and stress
fibers (Ebeling et al., 2014; Wardecki et al., 2016). Dry extract from
birch bark and its active marker substances strongly influence the
actin cytoskeleton, resulting in polarization of the cells, formation of
lamellipodia and filopodia at the leading edge, and stress fibers in the
cell body (Ebeling et al., 2014). Changes in actin cytoskeleton are also
evident in fibroblasts exposed to triterpene extracts and betulin
F IGURE 1 Overview of actions
of dry extract from birch bark and its
components during wound healing
process (Stage 1, inflammation; Stage
2, tissue and epidermal barrier
formation; Alakurtti et al., 2006,
Ebeling et al., 2014, Laszczyk, 2009,
Pastar et al., 2014, Woelfle et al.,
2010). Upper panels show stages of
wound healing. Lower panels show
the proposed effects of dry extract
from birch bark on these and other
processes. Note that effects of dry
extract from birch bark are
determined chiefly from in vitro
experiments. COX-2,
cyclooxygenase-2; IL, interleukin;
PDGF, platelet-derived growth
factor; TE, dry extract from birch
bark (triterpene extract); TGF-β,
transforming growth factor-β;
TRPC6, transient receptor potential
canonical (subtype) 6; VEGF, vascular
endothelial growth factor
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(Wardecki et al., 2016). Activity of dry extract from birch bark on the
actin cytoskeleton is dependent on the activation of Rho GTPases
(Ebeling et al., 2014).
2.3 | Effects on forming a new epidermal barrier
Differentiation of keratinocytes is—part of the second stage of wound
healing—is essential for reepithelialization and maintenance of the
skin barrier. Dry extract from birch bark promotes keratinocyte differ-
entiation in vitro and in vivo (Woelfle et al., 2010). Dry extract from
birch bark stimulated enhancement of differentiation appears to be
mediated at least in part by upregulation of the nonselective transient
receptor potential canonical (subtype) 6 (TRPC6), which regulates
keratinocyte calcium influx (Woelfle et al., 2010).
3 | OLEOGEL-S10: PRECLINICAL AND
CLINICAL STUDIES
Processes of wound healing in epidermolysis bullosa (EB) are not fully
understood (Bruckner-Tuderman & Mellerio, 2017), and the range of
mutations and different depths of cleavage define the variety of clini-
cal phenotypes (Fine et al., 2014). Oleogel-S10 does not treat the
underlying genetic defect in EB—in vitro data have shown that the
agent acts on common and general mechanisms of wound healing
(Ebeling et al., 2014). These data suggest that the effects of Oleogel-
S10 on wound healing in EB would be independent of disease sub-
type. Both the European Medicines Agency (EMA) in 2011, and the
Food and Drug Administration (FDA) in 2014, issued an orphan drug
designation for the active substance betulin for the indication of EB.
Preclinical studies of Oleogel-S10 have been conducted to evaluate
safety, tolerability, and toxicity. Parenteral repeated-dose toxicity studies
in rats and dogs showed no systemic changes related to the test sub-
stance, and a pronounced inflammatory, granulomatous reaction
observed at the injection site following subcutaneous administration in
dogs was considered as due to the insolubility of the triterpenes
(Alakurtti et al., 2006). Moreover, dermal application of Oleogel-S10 to
intact or abraded mini-pig skin did not result in any systemic toxicity and
was generally well tolerated. A high degree of tolerability was also
observed for maximal systemic exposure in juvenile animals (European
Medicines Agency, 2015).
Wounds of the skin can be compared to full or partial thickness
wounds, based on the depth of skin layers involved. The level of skin
cleavage in the major EB types/subtypes extends at maximum into
the upper part of the dermis, thus EB wounds resemble partial thick-
ness wounds (Denyer, Pillay, & Chlapham, 2017; Fine et al., 2014).
Sensory nerve endings in these wounds are abundant in the remaining
dermal tissue of the wound bed and there is also an increased risk of
infection due to the compromised skin barrier. Human skin and depth
of cutaneous wounds in EB are illustrated in Figure 2 (Fine et al.,
2014; Vogt & Ipaktchi, 2013).
Clinical data are available from one Phase 2 and three Phase
3 studies of the use of Oleogel-S10 in the treatment of partial thick-
ness wounds of different etiologies. In the Phase 3 setting, Oleogel-
S10 was found to accelerate wound healing in partial thickness
wounds in split thickness skin graft (STSG) donor site wounds (studies
BSH-12 and BSG-12) (Barret et al., 2017), and in Grade 2a burn
wounds (BBW-11) (Frew et al., 2018). In STSG donor site wounds, the
17-day healing period with standard treatment was reduced by
1–2 days (Barret et al., 2017). In Grade 2a burn wounds, the 9-day
F IGURE 2 Human skin and depth of cutaneous wounds in epidermolysis bullosa. Diagram shows the relationship between depth of injury in
partial thickness wounds (i.e., those sustained in graft surgery) and EB. EB, epidermolysis bullosa; EBS, EB simplex; JEB, junctional EB; KS, Kindler
syndrome; DEB, dystrophic EB
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healing period with standard treatment was reduced by 1 day (Frew
et al., 2018). Oleogel-S10 had a good overall safety profile in Phase
3 studies and appeared to be well tolerated. A further, single-centre,
Phase 3 study of 32 undergoing graft surgery showed quicker wound
closure and better viscoelastic properties of wounds treated with
Oleogel-S10 compared with controls (Lipovy et al., 2018).
As a result of formal Phases 2 and 3 studies, Oleogel-S10 received
a marketing authorization in the European Economic Area under the
tradename Episalvan® in January 2016 for the treatment of partial
thickness wounds in adults. It should be noted that the safety and
efficacy of Oleogel-S10 in children and adolescents under 18 years
have not yet been established.
A proof of concept Phase 2 study in patients with dystrophic EB
has suggested the potential for faster reepithelialization of wounds
treated with Oleogel-S10 (Schwieger-Briel, Kiritsi, Schempp, Has, &
Schumann, 2017). The primary efficacy variable in this study was
faster reepithelialization from baseline to either Day 14 or Day
28 (in case of delayed wound healing), as evaluated by two blinded
experts. A secondary outcome variable was percentage of wound epi-
thelialization. Twelve wound pairs were evaluated, in 10 patients with
dystrophic EB. For each wound pair, one was treated with Oleogel-
S10 plus nonadhesive wound dressing and the other with non-
adhesive wound dressing only (control). Oleogel-S10 plus non-
adhesive wound dressing accelerated the reepithelialization in eight of
eight decided cases (p = .0078, binomial test) (Schwieger-Briel et al.,
2017). In five cases, both blinded reviewers considered epithelializa-
tion of the wounds treated with Oleogel-S10 as superior; in three
cases only one reviewer considered Oleogel-S10 as superior and the
other one as equal to control; no case was scored in favor of control.
Four cases were undecided (i.e., investigators could not be decided
which wound or wound half showed faster reepithelization than the
other). Measurements of wound size showed a trend toward acceler-
ated wound healing with Oleogel-S10 but this was not statistically sig-
nificant. Touch sensitivity, itching, exudation, and efficacy as rated by
investigators and patients were comparable for both treatments.
These results indicate a potential for faster reepithelialization of
wounds in patients with dystrophic EB when treated with Oleogel-
S10 but larger studies are needed to confirm the significance of these
findings (Schwieger-Briel et al., 2017).
A global Phase 3 trial of Oleogel-S10 in EB is currently ongoing.
Efficacy And Safety of Oleogel S10 in patients with EB (EASE)
(NCT03068780; EudraCT No. 2016–002066-32) is a double-blind,
randomized, placebo-controlled, Phase 3, efficacy and safety study
with 24-month open-label follow-up of Oleogel-S10 in patients with
inherited EB (EU Clinical Trials Register, 2018). The primary objective
of the double-blind phase of the trial is to compare the efficacy of
Oleogel-S10 with placebo gel in the promotion of healing of EB partial
thickness wounds. This will be assessed as the incidence of the first
complete closure of the EB target wound: the primary efficacy end-
point is complete closure of the EB target wound within 45 ± 7 days
of treatment, and secondary objectives will include efficacy of treat-
ment as evidenced by other criteria described in the study protocol,
safety, tolerability, and exposure to betulin.
Bland creams or ointments are routinely applied to wounds to help
prevent wound crusting from serous exudate. As a gel, Oleogel-S10
may also contribute to this type of effect. Oleogel-S10 is also sterile and
its gel-like nature is likely to act as a physical barrier to infection, which
is an important consideration in the management of wounds associated
with EB. In common with other patients with chronic wounds, when
treating patients with significant EB-related wound burden, possible
issues with contact allergies (e.g., hydrocolloid dressings) may also need
to be considered (Muller & Kiritsi, 2017). To our knowledge, there is no
current literature on potential contact allergy to the individual compo-
nents of Oleogel-S10. However, there is a published case report of pos-
sible contact allergy with a cosmetically used emulsion that is based on
the dry extract of birch bark used in Oleogel-S10 (Meyer-Hoffert &
Brasch, 2013). Oleogel-S10 is considered safe to use for people who are
allergic to birch pollen, as these allergens are not present in the formu-
lated product (Amryt, 2015).
4 | OLEOGEL-S10 IN CONTEXT
EB affects approximately 1 in 17,000 live births and it is estimated
that there are around 500,000 people living with the condition world-
wide (figures from DEBRA International). EB is caused by more than
1,500 known mutations in at least 20 genes encoding anchoring and
other proteins of the dermoepidermal junction (Uitto, Bruckner-
Tuderman, McGrath, Riedl, & Robinson, 2018). More than 30 different
subtypes, inherited in either an autosomal dominant or recessive man-
ner and with varying clinical presentations, are currently recognized
(Fine, 2010; Fine et al., 2014; Uitto et al., 2018).
Currently, there is no cure for EB although research is progressing,
and, recently, the regeneration of a large part of the affected epider-
mis using transgenic stem cells was reported in a 7-year-old child with
a life-threatening form of junctional EB (Hirsch et al., 2017). Treat-
ment of patients with EB consists primarily of preventive and/or palli-
ative measures, together with supportive care to relieve itch and pain
(DEBRA International, 2018; Denyer et al., 2017; El Hachem et al.,
2014). Data from patients with partial thickness wounds and EB
treated with Oleogel-S10 have been encouraging, and it is possible
that future clinical practice guidelines could include the agent as a
component of the standard of care for EB.
5 | CONCLUSIONS
There are many different EB genotypes and phenotypes and currently
there is no effective pharmacological or genetic treatment option
for all subtypes (DEBRA International, 2016). Most commentators
acknowledge that causal treatment of EB will be achievable through
genetic intervention, but that this is a long-term aim due in part to
the number of mutated genes involved. Moreover, considering the
involved surfaces affected by fragility, even if genetic treatments
become more readily available, this will not necessarily mean a com-
plete cure of the disease. Until then, treatments to accelerate wound
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healing and provide relief of pain and itch are greatly appreciated and
urgently needed.
Oleogel-S10 has been shown to accelerate the reepithelialization
of wounds, and this is thought to be due to a bimodal pro- and anti-
inflammatory effect as well as an enhancement of keratinocyte migra-
tion and differentiation. Substantiation of the results of the concept
Phase 2 EB study with a randomized, placebo-controlled Phase 3 study
was started in April 2017 (EASE; NCT03068780) after a consultation
with the FDA and EMA. Results are expected in 2019.
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